At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed progressive or recurrent endometrial cancer with endometrioid or mixed endometrioid component histology (any grade)
- ✓Failed no more than two prior chemotherapies for recurrent disease (chemosensitizing radiation does not count)
- ✓Measurable disease by physical examination or imaging (ascites and pleural effusions do not qualify)
- ✓Zubrod performance status 0, 1, or 2
- ✕Prior treatment with RAD001 or any mTOR inhibitor
- ✕Serous carcinoma, mixed malignant mullerian tumors (MMMT), or uterine sarcoma components
- ✕Isolated recurrence amenable to curative radiation or surgery
- ✕History of myocardial infarction within 6 months or congestive heart failure requiring therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer
In Brief
A Phase 2 clinical trial evaluating RAD001 for Endometrial Cancer. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if RAD001 can shrink or slow the growth of tumors in patients who have recurrent endometrial cancer. The safety of this drug will also be studied. Objectives: Primary Objective: 1\. To determine the efficacy of RAD001 in patients with progressive or recurrent endometrial cancer. Secondary Objective: 1. To determine the nature and degree of toxicity of RAD001 in this cohort of patients. 2. To characterize, in pre- and post- treatment tumor samples, when available, expression levels of total and phosphorylated mTOR (mammalian "target of rapamycin") as well as relevant upstream and downstream signaling components (optional).
Study Details
Timeline
Interventions
10 mg by mouth Daily